Y Yang1, J Shen2, Jiaxi He2, Jianxing He2, G Jiang3. 1. Department of Thoracic Surgery, Shanghai Pulmonary Hospital affiliated Tongji University, Shanghai, China. 2. Department of Cardiothoracic Surgery, The First Affiliated Hospital of Guangzhou Medical University, Guangzhou, China. 3. Department of Thoracic Surgery, Shanghai Pulmonary Hospital affiliated Tongji University, Shanghai, China. jgn1121@163.com.
Abstract
INTRODUCTION: The aim of the study was to evaluate the effect of β-catenin immunohistochemical expression on the prognosis of lung cancer. MATERIALS AND METHODS: We searched Pubmed and Embase to identify eligible studies. The enrolled references were between January 1985 and January, 2015, with no lower date limit. The citation lists associated with the studies were used to identify additional eligible studies. The data of β-catenin immunohistochemical expression, clinical features and survival in each eligible article were recorded and analyzed as hazard ratio (HR) and odd ratio (OR). RESULTS: A total of 15 studies were identified and comprised 3404 cases. β-catenin expression was not significantly correlated with poor overall survival (OS) in lung cancer patients (HR 0.79, 95 % CI 0.47-1.34), but showed a significant degree of heterogeneity (I (2) = 95 %, P < 0.0001). Subgroup analysis indicated that accumulation in the nucleus or loss of membrane significantly influences the survival of lung cancer patients independently. But, the result indicated that β-catenin expression was not associated with clinicopathological features such as TNM stage (OR 1.22, 95 % CI 0.69-2.14), T stage (OR 0.86, 95 % CI 0.63-1.17), lymph node metastasis (0.85, 95 % CI 0.41-1.78), distant metastasis (OR 0.82, 95 % CI 0.31-2.18), grade of differentiation (OR 0.92, 95 % CI 0.47-1.80), or vascular invasion (OR 0.99, 95 % CI 0.04-24.10). CONCLUSION: Abnormal β-catenin immunohistochemical expression might be associated with tumor progression and could be a predictive factor of poor prognosis in patients with lung cancer based on more precise evaluation.
INTRODUCTION: The aim of the study was to evaluate the effect of β-catenin immunohistochemical expression on the prognosis of lung cancer. MATERIALS AND METHODS: We searched Pubmed and Embase to identify eligible studies. The enrolled references were between January 1985 and January, 2015, with no lower date limit. The citation lists associated with the studies were used to identify additional eligible studies. The data of β-catenin immunohistochemical expression, clinical features and survival in each eligible article were recorded and analyzed as hazard ratio (HR) and odd ratio (OR). RESULTS: A total of 15 studies were identified and comprised 3404 cases. β-catenin expression was not significantly correlated with poor overall survival (OS) in lung cancerpatients (HR 0.79, 95 % CI 0.47-1.34), but showed a significant degree of heterogeneity (I (2) = 95 %, P < 0.0001). Subgroup analysis indicated that accumulation in the nucleus or loss of membrane significantly influences the survival of lung cancerpatients independently. But, the result indicated that β-catenin expression was not associated with clinicopathological features such as TNM stage (OR 1.22, 95 % CI 0.69-2.14), T stage (OR 0.86, 95 % CI 0.63-1.17), lymph node metastasis (0.85, 95 % CI 0.41-1.78), distant metastasis (OR 0.82, 95 % CI 0.31-2.18), grade of differentiation (OR 0.92, 95 % CI 0.47-1.80), or vascular invasion (OR 0.99, 95 % CI 0.04-24.10). CONCLUSION: Abnormal β-catenin immunohistochemical expression might be associated with tumor progression and could be a predictive factor of poor prognosis in patients with lung cancer based on more precise evaluation.
Authors: N Murata-Kamiya; Y Kurashima; Y Teishikata; Y Yamahashi; Y Saito; H Higashi; H Aburatani; T Akiyama; R M Peek; T Azuma; M Hatakeyama Journal: Oncogene Date: 2007-01-22 Impact factor: 9.867
Authors: Cecilia Sahlgren; Maria V Gustafsson; Shaobo Jin; Lorenz Poellinger; Urban Lendahl Journal: Proc Natl Acad Sci U S A Date: 2008-04-21 Impact factor: 11.205
Authors: Jiajia Jin; Ping Zhan; Masaru Katoh; Susumu S Kobayashi; Kevin Phan; Hong Qian; Huijuan Li; Xiaoxia Wang; Xihua Wang; Yong Song Journal: Transl Lung Cancer Res Date: 2017-02
Authors: Lu Liu; Qiaoming Zhi; Meng Shen; Fei-Ran Gong; Binhua P Zhou; Lian Lian; Bairong Shen; Kai Chen; Weiming Duan; Meng-Yao Wu; Min Tao; Wei Li Journal: Oncotarget Date: 2016-07-26